Not FDA-approved2,3Evidence: Limited human dataHormones

Sermorelin1,2

Also called Geref2

Key takeaway

Sermorelin is a synthetic version of the first 29 amino acids of human growth hormone-releasing hormone. It was the active ingredient in Geref.1,2 FDA approved Geref in 1990 and 1997, but its maker stopped selling it in 2008 and FDA withdrew both approvals in 2009 at the maker’s request. FDA later determined that Geref was not withdrawn from sale for reasons of safety or effectiveness.2 Sermorelin does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.5,7

Sermorelin at a glance

What it isGrowth hormone-releasing factor (human) fragment 1 to 29, amidated, also recorded as groliberin, according to FDA’s substance registry.1
FDA statusNot FDA-approved. FDA withdrew the approvals of both Geref applications, NDA 019863 and NDA 020443, effective June 18, 2009, after the maker discontinued them, according to a 2013 Federal Register notice.2,3
Human evidenceOpen-label studies in children with growth hormone deficiency, such as a 1996 study of 110 children, and use as a diagnostic test.2,4
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is sermorelin?

Sermorelin is a 29-amino-acid peptide amide that matches the first 29 amino acids of human growth hormone-releasing hormone. FDA’s substance registry also records it as groliberin.1

It was the active ingredient of Geref, approved under NDA 019863 for testing the pituitary’s ability to release growth hormone and under NDA 020443 for idiopathic growth hormone deficiency in children with growth failure, according to FDA’s 2013 notice.2,3

How does sermorelin work?

Its registry name, growth hormone-releasing factor (human) fragment 1 to 29, reflects its action: like the natural hormone, it prompts the pituitary to release growth hormone.1

Geref’s diagnostic product was approved for evaluating the ability of the pituitary’s somatotroph cells to secrete growth hormone, according to FDA’s 2013 notice.2

What do human studies show?

In a 1996 open-label study, 110 previously untreated prepubertal children with growth hormone deficiency received sermorelin for up to a year; among 86 assessed, average growth rose from 4.1 to 8.0 centimetres a year at six months and was 7.2 at twelve months.4

The study authors reported no adverse changes in blood tests and no excessive rise in IGF-I. The study had no comparison group.4

What the evidence base contains

  • Small, short, or incompletely reported human study An open-label, multicenter study in 110 previously untreated children with growth hormone deficiency, without a comparison group, reported by the Geref International Study Group (1996).4

Evidence-strength label: Limited human data. How this label is assigned

Is sermorelin FDA-approved?

Not now. FDA’s March 4, 2013 Federal Register notice states that EMD Serono discontinued both Geref products in 2008 and asked FDA to withdraw their applications, and that approval of NDA 019863 and NDA 020443 was withdrawn effective June 18, 2009.2

In the same notice, FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness, which allows FDA to approve generic applications that refer to it if all other requirements are met. Drugs@FDA lists the Geref application as discontinued.2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list sermorelin, either in category 2 or among withdrawn nominations.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Sermorelin is not among them.6,7

Timeline

  1. FDA approves Geref for testing growth hormone release, NDA 019863, according to FDA’s 2013 notice.2
  2. The Geref International Study Group reports a one-year study of sermorelin in 110 children with growth hormone deficiency.4
  3. FDA approves Geref for growth hormone deficiency in children, NDA 020443.2,3
  4. FDA’s withdrawal of both Geref approvals takes effect, at the maker’s request, according to FDA’s 2013 notice.2
  5. FDA publishes its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness.2

What is still unknown?

How it compares with growth hormone itself, or how it affects final adult height: the 1996 study had no comparison group and followed children for a year.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Sermorelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Sermorelin are a bounded selection, not every registration or paper about Sermorelin. For the years before Sermorelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Sermorelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Sermorelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness. Human data come mainly from open-label studies in children with growth hormone deficiency, such as a 1996 study of 110 children. Sermorelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Sermorelin?

FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness. Human data come mainly from open-label studies in children with growth hormone deficiency, such as a 1996 study of 110 children. Sermorelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
6
Drugs@FDA applications
2

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?↗Source date October 20, 2021
  2. Literature metadata · added November 16, 2026

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.↗Source date October 25, 2018
  3. Regulatory · added November 16, 2026

    Federal Register notice 2013-04827↗Source date March 4, 2013

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Sermorelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

6Selected dated records
13Connected citations
6Populated source years1990–2021
2/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

2 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesEditorial 1Journal Article 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
2
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
6

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 6 dated records

Research hub

Explore the Sermorelin evidence record

Open all 6 records →
6Dated records
2Evidence types
6Cited public sources
6Source years

Change ledger

Recently changed for Sermorelin

Open all 6 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Federal Register notice 2013-04827

The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.

PeptideScanner change date
November 16, 2026
Cited source date
March 4, 2013
Evidence lane
Regulatory

Official-source collections

Source records for Sermorelin

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span December 28, 1990 to October 20, 2021. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 6

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?↗

    PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.↗

    PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Federal Register notice 2013-04827↗

    The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.↗

  4. Regulatory

    Federal Register notice E9-11628↗

    The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin.↗

  5. Regulatory

    Drugs@FDA application NDA020443↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients.↗

  6. Regulatory

    Drugs@FDA application NDA019863↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Sermorelin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗

    Federal Register · Official source · Source checked November 15, 2026

  3. 3
    Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  4. 4
    Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group (1996) · PMID 8772599 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026